A research team from Yale University in the U.S., in collaboration with global pharmaceutical company Boehringer Ingelheim, ...

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to ...

The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

Artificial intelligence and machine learning are being embedded in every aspect of the drug discovery and development process. In the preclinical stages, for example, companies are using advanced AI ...

“There are over 600,000 drugs in the Korea Chemical Bank alone. It felt overwhelming to find a drug that perfectly fits the protein structure we’re targeting among them. That’s when I thought of AI ...

The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...

Pharmaceutical innovation saves lives. But not every "new" drug is truly new. Such practices raise concerns about drug access and affordability, especially when companies use minor tweaks to block ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...